News & Updates

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

A 50,000-IU loading dose of oral vitamin D plus 8,000 IU daily is effective and safe for increasing serum 25(OH)D levels to ≥40 ng/mL in children and adolescents with asthma who were overweight or obese, as opposed to the standard of care (SoC) dose of 600 IU daily, according to findings from the VDORA1* trial.

The selective autotaxin inhibitor ziritaxestat shows therapeutic potential in patients with early diffuse cutaneous systemic sclerosis, conferring greater reductions in modified Rodnan skin score compared with placebo and potentially reducing fibrosis, according to data from the phase IIa NOVESA study.

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.